rewirebio.iobenchmarks
Evidence claim

Relevance of ctdnajam-20261010-protocol-ccga1-training-cv-sens-98spec to "Which fragmentomics workflow detects tumour-derived plasma DNA under realistic low tumour fractions and fixed false-positive constraints?"

Use case
Select a plasma ctDNA fragmentomics detection workflow
Assessed by
CCGA substudy 1 training set: cancer signal sensitivity at 98% specificity under 10-fold cross-validation
Relevance
Proxy evidence
Endpoint
Sensitivity (95% CI, TP/total) at 98% specificity under 10-fold cross-validation for the fragment endpoint, fragment length and allelic imbalance classifiers from 30x cfDNA WGS, alongside copy-number, mutation, whole-genome methylation and clinical classifiers on the same participants

Compares two fragmentomic classifiers with other cfDNA features on the same blood draws at a fixed false-positive rate. Proxy evidence: no tumour-fraction-stratified sensitivity is printed, the fragment classifiers were developed after unblinding, and the 98% threshold is post hoc.

9 reviewed evaluations

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

20 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-11-21-c8bea25e5abb
Property and statementOriginal source and locationReview and provenance
Citation locations
1 values
  • source id
    ctdnajam-20261010-source-jamshidi2022
    locator
    Table 3, training columns; STAR Methods
Context-only references
Evaluation of cell-free DNA approaches for multi-cancer early detection

Original source ↗

ctdnajam-20261010-source-jamshidi2022: Table 3, training columns; STAR Methods

Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1
Retrieved: 2026-10-10T06:05:17Z

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.citation_locators

Source artifact SHA-256: 5159294dd203d511dd437837a34555b276e14e0edf615bcb58bae5d9a1246d9a

Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py

Inspected artifact

Comparison group
jamshidi2022-ccga1-detection
Context-only references
Evaluation of cell-free DNA approaches for multi-cancer early detection

Original source ↗

ctdnajam-20261010-source-jamshidi2022: Table 3, training columns; STAR Methods

Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1
Retrieved: 2026-10-10T06:05:17Z

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.comparison_group

Source artifact SHA-256: 5159294dd203d511dd437837a34555b276e14e0edf615bcb58bae5d9a1246d9a

Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py

Inspected artifact

Comparison title
CCGA substudy 1: cfDNA classifiers on the same participants at a post hoc 98% specificity
Context-only references
Evaluation of cell-free DNA approaches for multi-cancer early detection

Original source ↗

ctdnajam-20261010-source-jamshidi2022: Table 3, training columns; STAR Methods

Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1
Retrieved: 2026-10-10T06:05:17Z

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.comparison_title

Source artifact SHA-256: 5159294dd203d511dd437837a34555b276e14e0edf615bcb58bae5d9a1246d9a

Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py

Inspected artifact

Constraints
3 values
  • Inspect every linked evaluation's source locator and preserved limitations before citing a result.
  • Do not combine this mapping's evaluations with any other protocol's results; cohorts, assays and thresholds differ.
  • The 98% specificity threshold was set post hoc within each set and is not a locked screening threshold.
Context-only references
Evaluation of cell-free DNA approaches for multi-cancer early detection

Original source ↗

ctdnajam-20261010-source-jamshidi2022: Table 3, training columns; STAR Methods

Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1
Retrieved: 2026-10-10T06:05:17Z

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.constraints

Source artifact SHA-256: 5159294dd203d511dd437837a34555b276e14e0edf615bcb58bae5d9a1246d9a

Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py

Inspected artifact

Endpoint
Sensitivity (95% CI, TP/total) at 98% specificity under 10-fold cross-validation for the fragment endpoint, fragment length and allelic imbalance classifiers from 30x cfDNA WGS, alongside copy-number, mutation, whole-genome methylation and clinical classifiers on the same participants
Context-only references
Evaluation of cell-free DNA approaches for multi-cancer early detection

Original source ↗

ctdnajam-20261010-source-jamshidi2022: Table 3, training columns; STAR Methods

Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1
Retrieved: 2026-10-10T06:05:17Z

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.endpoint

Source artifact SHA-256: 5159294dd203d511dd437837a34555b276e14e0edf615bcb58bae5d9a1246d9a

Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py

Inspected artifact

Claimed field
links:assessed_by:ctdnajam-20261010-protocol-ccga1-training-cv-sens-98spec
Context-only references
Evaluation of cell-free DNA approaches for multi-cancer early detection

Original source ↗

ctdnajam-20261010-source-jamshidi2022: Table 3, training columns; STAR Methods

Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1
Retrieved: 2026-10-10T06:05:17Z

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.field

Source artifact SHA-256: 5159294dd203d511dd437837a34555b276e14e0edf615bcb58bae5d9a1246d9a

Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py

Inspected artifact

Headline metric
sensitivity-at-98-percent-specificity
Context-only references
Evaluation of cell-free DNA approaches for multi-cancer early detection

Original source ↗

ctdnajam-20261010-source-jamshidi2022: Table 3, training columns; STAR Methods

Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1
Retrieved: 2026-10-10T06:05:17Z

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.headline_metric

Source artifact SHA-256: 5159294dd203d511dd437837a34555b276e14e0edf615bcb58bae5d9a1246d9a

Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py

Inspected artifact

Limitations
9 values
  • Developer study: GRAIL designed the assays and classifiers, ran every arm, and reports the comparison.
  • The 98% specificity threshold was set post hoc within each set, including the validation set, so it is not a threshold locked before validation.
  • Case-control enrolment of clinically diagnosed cancers and matched non-cancer participants, not an intended-use screening population.
  • Prototype assays; the targeted methylation test developed afterwards is a different assay and is not scored here.
  • The fragment endpoints, fragment lengths, allelic imbalance and pan-feature classifiers were developed after validation blinding was lifted; the other classifiers were blinded.
  • Table 3 scores 833 training and 464 validation cancers against 854 and 485 analysable cancers in Table 1. STAR Methods restrict detection to solid cancers, and Table 1 lists 11 plasma cell neoplasms and 10 leukaemias in training and 8 and 13 in validation, which is 21 in each set; lymphomas stay in.
  • Specificity was 97.9% (548/560) in training and 97.8% (354/362) in validation for every cfDNA classifier, slightly below the 98% target.
  • No sensitivity within tumour-fraction strata is printed; per-classifier clinical limits of detection by cTAF are in figures only.
  • The fragment endpoint, fragment length and allelic imbalance classifiers were developed after validation blinding was lifted, so their validation values are not a blinded validation, even though the source calls the cohort held-out; the copy-number, mutation, methylation and clinical rows were analysed double-blinded.
Context-only references
Evaluation of cell-free DNA approaches for multi-cancer early detection

Original source ↗

ctdnajam-20261010-source-jamshidi2022: Table 3, training columns; STAR Methods

Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1
Retrieved: 2026-10-10T06:05:17Z

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.limitations

Source artifact SHA-256: 5159294dd203d511dd437837a34555b276e14e0edf615bcb58bae5d9a1246d9a

Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py

Inspected artifact

Pinned records
21 values
  • record id
    ctdnajam-20261010-eval-training-allelic-imbalance
    fields
    • status
    • links
    • attributes.origin
    • attributes.comparison
    sha256
    d5dbae67229e48fd4758f574fda0db70d7ea0a0455d8d1105ee2c1fee4ba51ba
  • record id
    ctdnajam-20261010-eval-training-clinical-data
    fields
    • status
    • links
    • attributes.origin
    • attributes.comparison
    sha256
    1d52b51d39fa7581e10f3a7fc9011a7d0d58bbe4a0d40d22e728eeccb33136fb
  • record id
    ctdnajam-20261010-eval-training-fragment-endpoints
    fields
    • status
    • links
    • attributes.origin
    • attributes.comparison
    sha256
    3f6113038c4b589e58f6e01632f8296bed18a8e30d12e6c1ef26e442e7b651d5
  • record id
    ctdnajam-20261010-eval-training-fragment-lengths
    fields
    • status
    • links
    • attributes.origin
    • attributes.comparison
    sha256
    8baa47c31c3be9c7d563d758f452c12c125b42bce1f0f5eef59ed922c70fcb14
  • record id
    ctdnajam-20261010-eval-training-scna
    fields
    • status
    • links
    • attributes.origin
    • attributes.comparison
    sha256
    308b3a9f74982fbe8704819025d5434558cf07ab23b8b80e2c06d7ea9e36b864
  • record id
    ctdnajam-20261010-eval-training-scna-wbc
    fields
    • status
    • links
    • attributes.origin
    • attributes.comparison
    sha256
    d60a82250add685a70cec0035e890ff8cca597a2f18ee755711cda02d740da51
  • record id
    ctdnajam-20261010-eval-training-snv
    fields
    • status
    • links
    • attributes.origin
    • attributes.comparison
    sha256
    b192bf6cb8b40bfd6a9bac2d7e8e46dc3b8260dc3ba58443d7f4d4db21c5c9cc
  • record id
    ctdnajam-20261010-eval-training-snv-wbc
    fields
    • status
    • links
    • attributes.origin
    • attributes.comparison
    sha256
    9eeb50a8399c1e7382a39110181b54c03a30f28899434225f6090baf61fd98ad
  • record id
    ctdnajam-20261010-eval-training-wg-methylation
    fields
    • status
    • links
    • attributes.origin
    • attributes.comparison
    sha256
    ee219db71a2d985de4b230b91d409083aa64e21e996808f8df1bf3297e6562a9
  • record id
    ctdnajam-20261010-protocol-ccga1-training-cv-sens-98spec
    fields
    • status
    • name
    • description
    • facets
    • source_ids
    • links
    • attributes
    sha256
    989df2f01c0e0680982046687453cf8e01eaff06fdd2cef30b77956a4c047935
  • record id
    ctdnajam-20261010-result-training-allelic-imbalance-sensitivity
    fields
    • status
    • attributes.metric
    • attributes.metric_qualifier
    • attributes.printed_value
    • attributes.numeric_value
    sha256
    fe3448280770c20f1b54af865af886913eb02846288fc626da8bf6ca045a369b
  • record id
    ctdnajam-20261010-result-training-clinical-data-sensitivity
    fields
    • status
    • attributes.metric
    • attributes.metric_qualifier
    • attributes.printed_value
    • attributes.numeric_value
    sha256
    9aa5ea94d9bc7d5a2d13ca1fb78c40c6eb3ec8d957f7c10d44ef389c0dc3b25f
  • record id
    ctdnajam-20261010-result-training-fragment-endpoints-sensitivity
    fields
    • status
    • attributes.metric
    • attributes.metric_qualifier
    • attributes.printed_value
    • attributes.numeric_value
    sha256
    ffaa2d34ae152a077662dfdc8a9a0227dc236e856e7e6a983161aada80e04025
  • record id
    ctdnajam-20261010-result-training-fragment-lengths-sensitivity
    fields
    • status
    • attributes.metric
    • attributes.metric_qualifier
    • attributes.printed_value
    • attributes.numeric_value
    sha256
    f293f78f2dd57171218e475f5bb303b5da6516110e1735a9984467d04b3c582b
  • record id
    ctdnajam-20261010-result-training-scna-sensitivity
    fields
    • status
    • attributes.metric
    • attributes.metric_qualifier
    • attributes.printed_value
    • attributes.numeric_value
    sha256
    55800b64e75e349c9574302a38d6f4e067437e0161e3e02c76d784e3bfc486a0
  • record id
    ctdnajam-20261010-result-training-scna-wbc-sensitivity
    fields
    • status
    • attributes.metric
    • attributes.metric_qualifier
    • attributes.printed_value
    • attributes.numeric_value
    sha256
    473993745009b5df1d857d423f4dcb9e5c66f3f43e99ce6fb4397d3c6a81bebd
  • record id
    ctdnajam-20261010-result-training-snv-sensitivity
    fields
    • status
    • attributes.metric
    • attributes.metric_qualifier
    • attributes.printed_value
    • attributes.numeric_value
    sha256
    9c699789969b9519eb9134425fbb111acd7b94729d7dd9e2f08ab2d306436716
  • record id
    ctdnajam-20261010-result-training-snv-wbc-sensitivity
    fields
    • status
    • attributes.metric
    • attributes.metric_qualifier
    • attributes.printed_value
    • attributes.numeric_value
    sha256
    311545249c9bd2489f49e6fb53bf049a45a90e4987054e8f1088bb2cf8f7151e
  • record id
    ctdnajam-20261010-result-training-wg-methylation-sensitivity
    fields
    • status
    • attributes.metric
    • attributes.metric_qualifier
    • attributes.printed_value
    • attributes.numeric_value
    sha256
    3d870e6f22ac02c7ff9605e5bd212bbd87657fc2e225ec789da75e4b2ddd3f40
  • record id
    ctdnajam-20261010-source-jamshidi2022
    fields
    • status
    • attributes.artifact_sha256
    sha256
    49c49ed0c10c6121644dee3068618d9f5a06bbc63f5979bc8417acd9c1c0e56e
  • record id
    use-case-plasma-ctdna-fragmentomics
    fields
    • status
    • name
    • description
    • facets
    • attributes.question
    • attributes.decision
    • attributes.inputs
    • attributes.output
    • attributes.exclusions
    • attributes.setting
    • attributes.clinical_scope
    • attributes.intended_users
    sha256
    01d27c2ce64a391055bddc6dec9d5db208df9bee3d5e679045dd3f4f04a0ca08
Context-only references
Evaluation of cell-free DNA approaches for multi-cancer early detection

Original source ↗

ctdnajam-20261010-source-jamshidi2022: Table 3, training columns; STAR Methods

Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1
Retrieved: 2026-10-10T06:05:17Z

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.pins

Source artifact SHA-256: 5159294dd203d511dd437837a34555b276e14e0edf615bcb58bae5d9a1246d9a

Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py

Inspected artifact

Rationale
Compares two fragmentomic classifiers with other cfDNA features on the same blood draws at a fixed false-positive rate. Proxy evidence: no tumour-fraction-stratified sensitivity is printed, the fragment classifiers were developed after unblinding, and the 98% threshold is post hoc. The CCGA samples are not public and none of the cohorts behind this use case's existing judgements comes from CCGA, so the samples do not overlap.
Context-only references
Evaluation of cell-free DNA approaches for multi-cancer early detection

Original source ↗

ctdnajam-20261010-source-jamshidi2022: Table 3, training columns; STAR Methods

Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1
Retrieved: 2026-10-10T06:05:17Z

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.rationale

Source artifact SHA-256: 5159294dd203d511dd437837a34555b276e14e0edf615bcb58bae5d9a1246d9a

Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py

Inspected artifact

How to read the evidence

Sources and history

Release 2026-11-21-c8bea25e5abb · Record review: source checked

1 source record and release historyDownload this release (gzip)
Technical metadata and extraction receipts

Stable ID: use-case-mapping-ctdna-jamshidi-20261010-frag-training-cv

field
links:assessed_by:ctdnajam-20261010-protocol-ccga1-training-cv-sens-98spec
value
ctdnajam-20261010-protocol-ccga1-training-cv-sens-98spec
relevance
proxy
endpoint
Sensitivity (95% CI, TP/total) at 98% specificity under 10-fold cross-validation for the fragment endpoint, fragment length and allelic imbalance classifiers from 30x cfDNA WGS, alongside copy-number, mutation, whole-genome methylation and clinical classifiers on the same participants
rationale
Compares two fragmentomic classifiers with other cfDNA features on the same blood draws at a fixed false-positive rate. Proxy evidence: no tumour-fraction-stratified sensitivity is printed, the fragment classifiers were developed after unblinding, and the 98% threshold is post hoc. The CCGA samples are not public and none of the cohorts behind this use case's existing judgements comes from CCGA, so the samples do not overlap.
constraints
Inspect every linked evaluation's source locator and preserved limitations before citing a result.; Do not combine this mapping's evaluations with any other protocol's results; cohorts, assays and thresholds differ.; The 98% specificity threshold was set post hoc within each set and is not a locked screening threshold.
limitations
Developer study: GRAIL designed the assays and classifiers, ran every arm, and reports the comparison.; The 98% specificity threshold was set post hoc within each set, including the validation set, so it is not a threshold locked before validation.; Case-control enrolment of clinically diagnosed cancers and matched non-cancer participants, not an intended-use screening population.; Prototype assays; the targeted methylation test developed afterwards is a different assay and is not scored here.; The fragment endpoints, fragment lengths, allelic imbalance and pan-feature classifiers were developed after validation blinding was lifted; the other classifiers were blinded.; Table 3 scores 833 training and 464 validation cancers against 854 and 485 analysable cancers in Table 1. STAR Methods restrict detection to solid cancers, and Table 1 lists 11 plasma cell neoplasms and 10 leukaemias in training and 8 and 13 in validation, which is 21 in each set; lymphomas stay in.; Specificity was 97.9% (548/560) in training and 97.8% (354/362) in validation for every cfDNA classifier, slightly below the 98% target.; No sensitivity within tumour-fraction strata is printed; per-classifier clinical limits of detection by cTAF are in figures only.; The fragment endpoint, fragment length and allelic imbalance classifiers were developed after validation blinding was lifted, so their validation values are not a blinded validation, even though the source calls the cohort held-out; the copy-number, mutation, methylation and clinical rows were analysed double-blinded.
citation locators
source id: ctdnajam-20261010-source-jamshidi2022; locator: Table 3, training columns; STAR Methods
source locator
ctdnajam-20261010-source-jamshidi2022: Table 3, training columns; STAR Methods
revision
1
reason
Add the CCGA substudy 1 same-sample comparison of cfDNA classifiers (Jamshidi et al. 2022), retrieved 2026-10-10.
comparison group
jamshidi2022-ccga1-detection
comparison title
CCGA substudy 1: cfDNA classifiers on the same participants at a post hoc 98% specificity
headline metric
sensitivity-at-98-percent-specificity
stratum label
Training set, 10-fold cross-validation
stratum order
1
reviewed evaluations
ctdnajam-20261010-eval-training-allelic-imbalance; ctdnajam-20261010-eval-training-clinical-data; ctdnajam-20261010-eval-training-fragment-endpoints; ctdnajam-20261010-eval-training-fragment-lengths; ctdnajam-20261010-eval-training-scna; ctdnajam-20261010-eval-training-scna-wbc; ctdnajam-20261010-eval-training-snv; ctdnajam-20261010-eval-training-snv-wbc; ctdnajam-20261010-eval-training-wg-methylation
review
method: automated-source-review; reviewer: claude; reviewer note: Separate Claude review agent, independent of the extractor; no human review claimed; reviewed at: 2026-10-10T09:00:00Z; note: Independent review of endpoint fit, relevance grade, limitations, exclusions and grouping against the use case and the article; every value of the listed evaluations was checked against Table 3 or the Results text, with percentages and Clopper-Pearson intervals recomputed. Developer study; no execution, reproduction, human scientific review or clinical validation.
pins
record id: ctdnajam-20261010-eval-training-allelic-imbalance; fields: status; links; attributes.origin; attributes.comparison; sha256: d5dbae67229e48fd4758f574fda0db70d7ea0a0455d8d1105ee2c1fee4ba51ba; record id: ctdnajam-20261010-eval-training-clinical-data; fields: status; links; attributes.origin; attributes.comparison; sha256: 1d52b51d39fa7581e10f3a7fc9011a7d0d58bbe4a0d40d22e728eeccb33136fb; record id: ctdnajam-20261010-eval-training-fragment-endpoints; fields: status; links; attributes.origin; attributes.comparison; sha256: 3f6113038c4b589e58f6e01632f8296bed18a8e30d12e6c1ef26e442e7b651d5; record id: ctdnajam-20261010-eval-training-fragment-lengths; fields: status; links; attributes.origin; attributes.comparison; sha256: 8baa47c31c3be9c7d563d758f452c12c125b42bce1f0f5eef59ed922c70fcb14; record id: ctdnajam-20261010-eval-training-scna; fields: status; links; attributes.origin; attributes.comparison; sha256: 308b3a9f74982fbe8704819025d5434558cf07ab23b8b80e2c06d7ea9e36b864; record id: ctdnajam-20261010-eval-training-scna-wbc; fields: status; links; attributes.origin; attributes.comparison; sha256: d60a82250add685a70cec0035e890ff8cca597a2f18ee755711cda02d740da51; record id: ctdnajam-20261010-eval-training-snv; fields: status; links; attributes.origin; attributes.comparison; sha256: b192bf6cb8b40bfd6a9bac2d7e8e46dc3b8260dc3ba58443d7f4d4db21c5c9cc; record id: ctdnajam-20261010-eval-training-snv-wbc; fields: status; links; attributes.origin; attributes.comparison; sha256: 9eeb50a8399c1e7382a39110181b54c03a30f28899434225f6090baf61fd98ad; record id: ctdnajam-20261010-eval-training-wg-methylation; fields: status; links; attributes.origin; attributes.comparison; sha256: ee219db71a2d985de4b230b91d409083aa64e21e996808f8df1bf3297e6562a9; record id: ctdnajam-20261010-protocol-ccga1-training-cv-sens-98spec; fields: status; name; description; facets; source_ids; links; attributes; sha256: 989df2f01c0e0680982046687453cf8e01eaff06fdd2cef30b77956a4c047935; record id: ctdnajam-20261010-result-training-allelic-imbalance-sensitivity; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: fe3448280770c20f1b54af865af886913eb02846288fc626da8bf6ca045a369b; record id: ctdnajam-20261010-result-training-clinical-data-sensitivity; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 9aa5ea94d9bc7d5a2d13ca1fb78c40c6eb3ec8d957f7c10d44ef389c0dc3b25f; record id: ctdnajam-20261010-result-training-fragment-endpoints-sensitivity; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: ffaa2d34ae152a077662dfdc8a9a0227dc236e856e7e6a983161aada80e04025; record id: ctdnajam-20261010-result-training-fragment-lengths-sensitivity; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: f293f78f2dd57171218e475f5bb303b5da6516110e1735a9984467d04b3c582b; record id: ctdnajam-20261010-result-training-scna-sensitivity; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 55800b64e75e349c9574302a38d6f4e067437e0161e3e02c76d784e3bfc486a0; record id: ctdnajam-20261010-result-training-scna-wbc-sensitivity; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 473993745009b5df1d857d423f4dcb9e5c66f3f43e99ce6fb4397d3c6a81bebd; record id: ctdnajam-20261010-result-training-snv-sensitivity; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 9c699789969b9519eb9134425fbb111acd7b94729d7dd9e2f08ab2d306436716; record id: ctdnajam-20261010-result-training-snv-wbc-sensitivity; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 311545249c9bd2489f49e6fb53bf049a45a90e4987054e8f1088bb2cf8f7151e; record id: ctdnajam-20261010-result-training-wg-methylation-sensitivity; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 3d870e6f22ac02c7ff9605e5bd212bbd87657fc2e225ec789da75e4b2ddd3f40; record id: ctdnajam-20261010-source-jamshidi2022; fields: status; attributes.artifact_sha256; sha256: 49c49ed0c10c6121644dee3068618d9f5a06bbc63f5979bc8417acd9c1c0e56e; record id: use-case-plasma-ctdna-fragmentomics; fields: status; name; description; facets; attributes.question; attributes.decision; attributes.inputs; attributes.output; attributes.exclusions; attributes.setting; attributes.clinical_scope; attributes.intended_users; sha256: 01d27c2ce64a391055bddc6dec9d5db208df9bee3d5e679045dd3f4f04a0ca08
Related records

Suggest a correction